Loading stock data…
$7.85-0.25 (-3.09%)
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CorMedix Inc. in the Healthcare sector is trading at $7.85 with a market capitalization of $610M. Wall Street consensus targets $15.33 (6 analysts), implying a +95.3% move over the next 12 months. The stock is currently 40% below its 52-week high of $13.02, remaining 2.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $99.31M↓ | $127.43M↓ | $128.62M↑ | $104.28M↑ | $39.74M |
| Gross Profit | $74.50M↓ | $105.12M↓ | $107.31M↑ | $93.08M↑ | $37.87M |
| Operating Income | $42.91M↓ | $63.66M↑ | $59.13M↑ | $51.35M↑ | $19.54M |
| Net Income | $25.99M↓ | $38.60M↑ | $14.02M↓ | $108.56M↑ | $19.83M |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solu...